Organism: Homo sapiens
Gene: 39533_at
Selected probe(set): 203580_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39533_at (203580_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):3.7288952
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.4916754
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-3.2261133
Number of Samples:2 / 6

Experimental	retina pigment epithelium study 1 (adult)
	Postmortem human native retina pigment epithelium samples from adult individuals.
Control	retina pigment epithelium study 1 (fetal)
	Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

Relative Expression (log2-ratio):-3.0254965
Number of Samples:4 / 8

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.9151335
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 DICER1(-/-) cell sample
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.8844986
Number of Samples:8 / 12

Experimental	hepatocyte (ESC)
	Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control	HepaRG
	Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

Relative Expression (log2-ratio):-2.8764057
Number of Samples:7 / 8

Experimental	dendritic cell study 6 (gardiquimod)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.8172073
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

Relative Expression (log2-ratio):-2.7638435
Number of Samples:4 / 4

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (CpG A; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.7410593
Number of Samples:7 / 5

Experimental	hepatoblastoma study 1 (embryonal)
	Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control	normal liver tissue
	Normal liver tissue samples.